Premium
THE ANTIBODY‐DRUG CONJUGATE (ADC) LONCASTUXIMAB TESIRINE (ADCT‐402) TARGETING CD19 SHOWS STRONG IN VITRO ANTI‐LYMPHOMA ACTIVITY BOTH AS SINGLE AGENTS AND IN COMBINATION
Author(s) -
Tarantelli C.,
Spriano F.,
Golino G.,
Gaudio E.,
Scalise L.,
Cascione L.,
Zucca E.,
Berkel P.,
Stathis A.,
Zammarchi F.,
Bertoni F.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.90_2629
Subject(s) - antibody drug conjugate , chemistry , diffuse large b cell lymphoma , lymphoma , ic50 , cancer research , pharmacology , cd19 , in vitro , antibody , immunology , medicine , monoclonal antibody , biochemistry